


Originating in 2006, the (LeiomyoSarcoma Support and Direct Research) LMSDR foundation is an all-volunteer staff of patients and caregivers, who are passionate about supporting others and helping researchers to find treatments that will work. We have as few expenses as possible, so nearly every penny goes to fund promising LMS research. Research, patient education and support, advocacy, awareness and collaboration is at the heart of what we do.



**Awarded over \$2,000,000 for LMS Research in the last 17 years**

2006: Microarray analysis of LMS from the paraffin tumor blocks donated by LMS patients worldwide (\$40,000: Dr. M. van de Rijn, Stanford)

2007: "Let-7 repression leads to HMGA2 overexpression in uterine leiomyosarcoma." (\$25,000: Dr. E. Hernando, New York University School of Medicine)

2008: "Discovery of Molecular Subtypes in Leiomyosarcoma through Integrated Molecular Profiling." (\$50,000: Drs. M. van de Rijn (Stanford), C.D. Fletcher (Dana Farber) and Coreless (Washington State University))

2009: "Prognostic Significance of Macrophage Infiltration in Leiomyosarcomas." (\$50,000: Dr. M. van de Rijn, Stanford)

2009 and 2010: "A Role for BRCA1 in Uterine Leiomyosarcoma." (Total \$50,000: Dr. S. Orsulic, Cedars Sinai)

2011: ROR2 is a Novel Prognostic Biomarker and a Potential Therapeutic Target in Leiomyosarcoma.

- The Effect of Mir-17-92 Dysregulation in Leiomyosarcoma-Genesis.
- Antibody Therapy Targeting the CD47 Protein is Effective in a Model of Aggressive Metastatic Leiomyosarcoma
- Flipping the Script on Macrophages in Leiomyosarcoma
- CFS1 Expression in Nongynecological Leiomyosarcoma is Associated with Increased Tumor Angiogenesis

(\$50,000 awarded jointly by LMSDR and the Liddy Shriver Sarcoma Initiative: Dr. M. van de Rijn, Stanford)

2013: The Study of Three Therapeutic Targets in Leiomyosarcoma

- Engineered SIRPa Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies.
- Comparative Gene Expression Profiling of Benign and Malignant Lesions Reveals Candidate Therapeutic Compounds for Leiomyosarcoma

(\$50,000 awarded along with \$100,000 from the Liddy Shriver Sarcoma Initiative: Dr. M. van de Rijn, Stanford)

2014 and 2015: "Using Circulating Tumor DNA as a Measure of Tumor Load and Response to Therapy."

- Clinically Relevant Molecular Subtypes in Leiomyosarcoma.
- A Role for Versican in the Development of Leiomyosarcoma.
- Progressive Loss of Myogenic Differentiation in Leiomyosarcoma Has Prognostic Value.

(\$110,000 in 2014 and \$110,000 in 2015: Dr. M. van de Rijn, Stanford)

2016: "Maximizing Therapeutic Response in LMS" (\$125,000: Drs. C.D. Fletcher (Dana Farber), M. van de Rijn (Stanford), F. Chibon (France's Bergonie Institute), S. Bauer (West German Cancer Center) and D. Langenau (Massachusetts General Hospital.) Co-funded collaboratively with the Liddy Shriver Foundation and National Leiomyosarcoma Foundation)

2017: ART Inhibition in ALT Positive Leiomyosarcoma and Osteosarcoma. \$2,000: Dr G. Cote, Massachusetts, funded by the Lissy McMahon Memorial fund.

2017: ROR2 and a Potential Target in LMS (\$40,000 Dr. M. van de Rijn, Stanford)

2017, 2018 and 2020: "Using Circulating Tumor DNA as a Measure of Tumor Load and Response to Therapy." (\$90,000 in 2017, \$140,000 in 2018 and \$100,000 in 2020: Dr. M. van de Rijn, Stanford)

2018 and 2019: "Exploring LMS Functional Genomics to Identify Disease Specific Vulnerabilities." (\$42,000 in 2018 and \$47,000 in 2019: Dr. M. Hemming, Dana Farber)

2018: "Identification of a Novel Treatment Strategy for Uterine Leiomyosarcoma in Genotype Defined Patient Population." (\$74,000: Dr T. Omelchenko, Sloan Kettering)

2018: "Kicking the Hornets Nest." (\$10,000: K. Floyd for his documentary, documenting the history of uterine morcellation and the consequences for women with leiomyosarcoma)

2019 and 2020: New targets for LMS, including the role of TP53, pten, p13K and mTOR. (\$100,000 in 2019 and \$150,000 in 2020: SARC – Sarcoma Alliance for Research Collaboration)

2021: "Identifying Biomarkers Predictive of Benefit to Rucaparib and Nivolumab in Patients with Advanced Leiomyosarcoma." (\$100,000: Dr. S. Movva, Sloan Kettering)

2021: "Metabolic Reprogramming in Leiomyosarcoma." (\$100,000: Dr. J. Przybyl, Stanford)

2021: "Biological pathways and immune landscape associated with Gem/Tax therapy resistance and response in LMS." (\$50,000, The Debbie Foley Grant: Dr. P. Huang (Royal Marsden UK) and Dr. J. Przybyl (Stanford)

2022: Development of an Immune Biomarker for Metastatic Disease in Retroperitoneal LMS (\$100,000: Dr. W. Tseng, City of Hope Duarte, California)

2022: Novel Treatments of Leiomyosarcoma, using validated LMS cell lines to check the ability of best FOXM1 inhibitor either ± PROTACs, ETC-168 or Doxorubicin to retard growth of LMS (\$100,000: Dr. H. P. Koeffler, Cedars Sinai)

2023: Starting from an N of 1: Integrating genomic, analytic and functional analyses to establish a real-time treatment discovery and validation platform (\$50,000: Dr J. A. Martignetti, Mount Sinai)

2023: Liquid biopsy for uterine leiomyosarcoma (\$50,000 awarded to Dr. J. Przybyl, McGill University in partnership with the Sarcoma Alliance for Research through Collaboration (SARC) Catalyst program)

